Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus (NASDAQ:TEM)/b) announced a proposed private offering of
Lucent Diagnostics and Tempus AI (NASDAQ: TEM) announced a collaboration to integrate the LucentAD® Complete blood-based Alzheimer’s biomarker panel into Tempus Next care gap workflows and the Tempus clinical ordering platform.
The agreement makes LucentAD Complete available for neurologists to order via existing EHR integrations, aims to embed guideline-directed patient identification, and seeks to increase evaluation of patients eligible for approved Alzheimer’s treatments.
Tempus (NASDAQ: TEM) reported Q1 2026 revenue of $348.1M, up 36.1% year‑over‑year, with Diagnostics revenue of $261.1M (+34.7%) and Data & Applications revenue of $87.0M (+40.5%). Gross profit was $222.0M. Cash and marketable securities totaled $643.8M as of March 31, 2026. Net loss was $(125.9M); Adjusted EBITDA was $(2.8M). Tempus raised 2026 revenue guidance to $1.59–$1.60B and expects ~$65M Adjusted EBITDA for the year.
Tempus (NASDAQ:TEM) will host its inaugural Investor Day on May 29, 2026, starting at 8:00 a.m. CT / 9:00 a.m. ET. Leadership presenters include CEO Eric Lefkofsky, CFO Jim Rogers, and heads of Diagnostics, Data & Applications, plus CSO Kate Sasser, PhD.
The program covers presentations from Diagnostics and Data & Applications. A live webcast will be available and a recording will be posted on the Tempus investor website; in-person attendance is by invitation only.
Tempus (NASDAQ: TEM) was named to TIME’s 10 Most Influential Health and Life Science Companies of 2026 for advancing precision medicine through AI-driven genomic and clinical analysis. Highlights include FDA-approved xT CDx (648-gene tissue NGS test), the acquisition of Ambry Genetics, and collaborations with AstraZeneca and Pathos AI.
Tempus says the recognition reflects progress scaling multimodal AI insights across oncology, cardiology, neuropsychiatry, and more.
Median Technologies (TEM) reported FY2025 results and Q1 2026 highlights, including FDA 510(k) clearance for eyonis® LCS and a record iCRO order backlog of €79.8m as of March 31, 2026. Cash was €14.0m at March 31, 2026, with potential additional proceeds of ~€44.4m from warrants, and a 28% reduction in operating loss year‑over‑year.
Tempus (NASDAQ:TEM) and the Keck School of Medicine of USC announced a multi-faceted collaboration on April 23, 2026 to apply AI and molecular diagnostics across USC-affiliated hospitals.
The program targets clinical impact across more than 1.5 million annual patient visits and rests on four pillars: clinical testing integration, automated clinical trial matching, AI-driven care gap pathways, and joint research and AI co-development.
The partnership aims to speed translation of academic discoveries into validated diagnostics and therapies while connecting research to clinical workflows.
Tempus (NASDAQ:TEM) will report financial results for the quarter ended March 31, 2026, on Tuesday, May 5, 2026. A conference call and live audio webcast will be held at 4:30 p.m. ET to discuss results and provide a business update.
The call will be led by Founder and CEO Eric Lefkofsky and CFO Jim Rogers. The live audio webcast is available via the company Events page; a recording will be posted after the call. Conference ID: 4294068. Dial-in numbers and webcast link provided.
Tempus (NASDAQ: TEM) and Predicta Biosciences announced commercial expansion of a co-branded ultrasensitive whole-genome sequencing assay, GenoPredicta, for genomic characterization of hematologic malignancies and measurable residual disease (MRD) monitoring.
The assay integrates flow cytometry with WGS, detects alterations from as few as 50 tumor cells (sensitivity ~1-in-1,000,000), is clinically validated in multiple myeloma, and is available to Tempus life sciences partners for research and clinical development.
Tempus (NASDAQ: TEM) announced acceptance of 31 abstracts, including one oral presentation, for the AACR Annual Meeting 2026 (April 17–22) in San Diego. The company will present multimodal AI and sequencing research across colorectal, lung, GI, and pan‑cancer studies and host an Exhibitor Spotlight Theater session on April 20.